Payment overview · 2025
General Payments
$5,662.42
52 reported records · 15 companies
Healthcare provider profile · identity verified
Peter P. Chang, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANGELO, TX · NPI 1780688028
Verified facts
What the public records show
CMS Open Payments records show Peter P. Chang, MD received $5,662.42 in general payments during 2025 across 52 reported records.
ABBVIE INC. accounted for 85.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic, Ubrelvy, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $4,860.55 | 85.8% | 18 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $388.07 | 6.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.58 | 1.1% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $51.99 | 0.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.00 | 0.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.31 | 0.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.52 | 0.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.99 | 0.7% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $25.43 | 0.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 0.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.74 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.60 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.97 | 0.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.92 | 0.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $13.53 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $4,675.00 | 4 |
| Food and Beverage | $967.20 | 47 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $2,550.00 | 3 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $2,125.00 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $388.07 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.70 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.70 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.41 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.44 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $51.99 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $51.00 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.13 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.13 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 94 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 146 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
146 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1630 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1434 | 151 |
| Lisinopril | Lisinopril | 1211 | 155 |
| Gabapentin | Gabapentin | 1096 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1033 | 112 |
| Furosemide | Furosemide | 990 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 854 | 122 |
| Donepezil Hcl | Donepezil Hcl | 786 | 53 |
| Trazodone Hcl | Trazodone Hcl | 763 | 96 |
| Sertraline Hcl | Sertraline Hcl | 695 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 627 | 121 |
| Metformin Hcl | Metformin Hcl | 592 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 579 | 81 |
| Potassium Chloride | Potassium Chloride | 570 | 79 |
| Omeprazole | Omeprazole | 532 | 94 |
| Mirtazapine | Mirtazapine | 488 | 54 |
| Meloxicam | Meloxicam | 469 | 94 |
| Lorazepam | Lorazepam | 440 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 433 | 55 |
| Levetiracetam | Levetiracetam | 424 | 20 |
| Tramadol Hcl | Tramadol Hcl | 387 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 385 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 51 |
| Memantine Hcl | Memantine Hcl | 373 | 23 |
| Buspirone Hcl | Buspirone Hcl | 356 | 37 |
| Montelukast Sodium | Montelukast Sodium | 316 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 296 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 291 | 59 |
| Carvedilol | Carvedilol | 285 | 45 |
| Glipizide | Glipizide | 272 | 51 |
| Klor-Con M20 | Potassium Chloride | 259 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 255 | 61 |
| Azithromycin | Azithromycin | 252 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 36 |
| Alprazolam | Alprazolam | 246 | 37 |
| Allopurinol | Allopurinol | 235 | 34 |
| Losartan Potassium | Losartan Potassium | 222 | 43 |
| Eliquis | Apixaban | 220 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 214 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 207 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 204 | suppressed |
| Spironolactone | Spironolactone | 201 | 26 |
| Finasteride | Finasteride | 200 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 28 |
| Pregabalin | Pregabalin | 193 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 67 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 176 | suppressed |
| Bupropion Xl | Bupropion Hcl | 174 | 27 |
| Divalproex Sodium | Divalproex Sodium | 171 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 171 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 171 | suppressed |
| Clonazepam | Clonazepam | 170 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 164 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 156 | 103 |
| Olanzapine | Olanzapine | 154 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 153 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 152 | 15 |
| Midodrine Hcl | Midodrine Hcl | 150 | 12 |
| Myrbetriq | Mirabegron | 149 | 12 |
| Mounjaro | Tirzepatide | 146 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 144 | 23 |
| Januvia | Sitagliptin Phosphate | 143 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 136 | 17 |
| Simvastatin | Simvastatin | 132 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 118 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 20 |
| Prednisone | Prednisone | 115 | 22 |
| Topiramate | Topiramate | 109 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 107 | suppressed |
| Famotidine | Famotidine | 107 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 106 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 104 | suppressed |
| Ozempic | Semaglutide | 103 | 31 |
| Aripiprazole | Aripiprazole | 99 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 26 |
| Linzess | Linaclotide | 94 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 21 |
| Promethazine Hcl | Promethazine Hcl | 88 | 17 |
| Diazepam | Diazepam | 87 | 14 |
| Alendronate Sodium | Alendronate Sodium | 85 | 14 |
| Jardiance | Empagliflozin | 84 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | suppressed |
| Levofloxacin | Levofloxacin | 81 | 59 |
| Baclofen | Baclofen | 80 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | suppressed |
| Ezetimibe | Ezetimibe | 75 | suppressed |
| Lactulose | Lactulose | 75 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 72 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 71 | 16 |
| Atenolol | Atenolol | 69 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 68 | 12 |
| Digoxin | Digoxin | 68 | suppressed |
| Gemfibrozil | Gemfibrozil | 68 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 67 | suppressed |
| Estradiol | Estradiol | 63 | 19 |
| Latanoprost | Latanoprost | 63 | suppressed |
| Sucralfate | Sucralfate | 63 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | suppressed |
| Gemtesa | Vibegron | 62 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | suppressed |
| Methylprednisolone | Methylprednisolone | 61 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 59 | 59 |
| Risperidone | Risperidone | 59 | suppressed |
| Amantadine | Amantadine Hcl | 58 | suppressed |
| Methocarbamol | Methocarbamol | 58 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 58 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 38 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 53 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 12 |
| Haloperidol | Haloperidol | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 50 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 50 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 49 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Mupirocin | Mupirocin | 48 | 21 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 47 | suppressed |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Rasagiline Mesylate | Rasagiline Mesylate | 47 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 44 | suppressed |
| Eszopiclone | Eszopiclone | 43 | 11 |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 42 | 22 |
| Ondansetron Odt | Ondansetron | 41 | 28 |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 40 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 28 |
| Ziprasidone Hcl | Ziprasidone Hcl | 39 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Nystop | Nystatin | 37 | 17 |
| Desmopressin Acetate | Desmopressin Acetate | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 20 |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 21 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Lubiprostone | Lubiprostone | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Acyclovir | Acyclovir | 31 | suppressed |
| Metolazone | Metolazone | 31 | suppressed |
| Nystatin | Nystatin | 31 | 13 |
| Valsartan | Valsartan | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 12 |
| Cephalexin | Cephalexin | 30 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Dexamethasone | Dexamethasone | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 19 |
| Minocycline Hcl | Minocycline Hcl | 26 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 17 |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Armour Thyroid | Thyroid,pork | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Nadolol | Nadolol | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Motegrity | Prucalopride Succinate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Xcopri | Cenobamate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,662.42 · 52 records | ABBVIE INC. | ARISTADA, Auvelity, BOTOX, BREZTRI, DURYSTA, FANAPT, IBSRELA, INGREZZA, JOURNAVX, Kerendia, LINZESS, LYBALVI, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Wegovy, XEN GLAUCOMA TREATMENT SYSTEM, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error